Cencora (COR) is back on investors’ radar after updating its fiscal 2026 outlook, raising adjusted EPS expectations while projecting lower revenue growth, along with a new CAR T distribution agreement with Kite, a Gilead Company.

The updated fiscal 2026 guidance and CAR T agreement appear to have helped the share price regain some ground in the short term, with a 1 month share price return of 5.35%. However, momentum has cooled, with a 3 month share price decline of 23.98% and a 1 year total shareholder return of 4.09% in the red, compared with a much stronger 3 year total shareholder return of 58.35% and 5 year total shareholder return of 141.64%.

If this kind of healthcare logistics story interests you, it can be useful to see what else is moving by checking out 39 healthcare AI stocks

With Cencora trading at $275.04 and management guiding to higher adjusted EPS despite softer revenue growth, plus a fresh CAR T distribution deal, should you view the current price as a potential entry point, or conclude that the market is already fully reflecting expectations for future growth?

Most Popular Narrative: 22.9% Undervalued

Against Cencora's last close of $275.04, the most followed narrative pegs fair value at $356.83 per share, using a 7.11% discount rate and detailed long term earnings assumptions.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

Curious what sits behind that fair value gap? The narrative leans on measured revenue growth, firmer margins and a richer future earnings multiple. The exact mix may surprise you.

Result: Fair Value of $356.83 (UNDERVALUED)

However, you should also keep an eye on pressure from lower fee generics and biosimilars, as well as weaker international specialty logistics, which could weigh on margins and earnings power.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Mixed signals or an emerging opportunity, either way it pays to move quickly, review the full picture and weigh both the 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop here, you risk missing other stocks that could better fit your goals, so use the tools available and stay one step ahead.

• Target reliable income by scanning for companies screened as potential 9 dividend fortresses that might support a steadier cash return profile.
• Hunt for value by focusing on 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their business strength.
• Prioritize resilience by filtering for 61 resilient stocks with low risk scores so you can concentrate on companies with stronger overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.